Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer.
SCLC
blood parameters
chemoradiotherapy
immune scores
prognostic factor
survival
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
22
11
2020
revised:
10
12
2020
accepted:
21
12
2020
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
Previous studies have suggested the prognostic value of the Lung Immune Prediction Index (LIPI) and the Gustave Roussy Score (GRIM) as prognostic markers in advanced small cell lung cancer (SCLC). However, LIPI and GRIM score have not been evaluated in patients with limited stage SCLC (LS-SCLC). Pretreatment LIPI and GRIM score of 33 (43%) patients out of 77 LS-SCLC patients treated with chemoradiotherapy (CRT) during 2004-2015 were included. The median overall survival (OS) time in the good, intermediate, and poor LIPI subgroups were 14, 17 and 3 months (p=0.973) and 14, 17 and 17 months in the GRIM subgroups. In univariate analysis, patients age <65 years (p=0.008), concurrent chemotherapy (p=0.028), and administering prophylactic cranial irradiation (PCI) (p=0.031) were associated with improved OS. Using Cox regression analysis, age remained significant (HR=3.299, p=0.031) and PCI showed a trend (HR=2.801, p=0.06). Independent predictors of overall survival were identified and can contribute to improved treatment personalization. Concurrent chemotherapy and PCI after CRT were associated with improved OS compared to LIPI- and GRIM-score, which had no prognostic impact in LS-SCLC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Previous studies have suggested the prognostic value of the Lung Immune Prediction Index (LIPI) and the Gustave Roussy Score (GRIM) as prognostic markers in advanced small cell lung cancer (SCLC). However, LIPI and GRIM score have not been evaluated in patients with limited stage SCLC (LS-SCLC).
PATIENTS AND METHODS
METHODS
Pretreatment LIPI and GRIM score of 33 (43%) patients out of 77 LS-SCLC patients treated with chemoradiotherapy (CRT) during 2004-2015 were included.
RESULTS
RESULTS
The median overall survival (OS) time in the good, intermediate, and poor LIPI subgroups were 14, 17 and 3 months (p=0.973) and 14, 17 and 17 months in the GRIM subgroups. In univariate analysis, patients age <65 years (p=0.008), concurrent chemotherapy (p=0.028), and administering prophylactic cranial irradiation (PCI) (p=0.031) were associated with improved OS. Using Cox regression analysis, age remained significant (HR=3.299, p=0.031) and PCI showed a trend (HR=2.801, p=0.06).
CONCLUSION
CONCLUSIONS
Independent predictors of overall survival were identified and can contribute to improved treatment personalization. Concurrent chemotherapy and PCI after CRT were associated with improved OS compared to LIPI- and GRIM-score, which had no prognostic impact in LS-SCLC.
Identifiants
pubmed: 33622885
pii: 35/2/929
doi: 10.21873/invivo.12333
pmc: PMC8045058
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
929-935Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Q J Nucl Med Mol Imaging. 2020 Jun;64(2):162-174
pubmed: 32107903
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
Lung. 2020 Feb;198(1):201-206
pubmed: 31897594
Lung. 2016 Apr;194(2):295-8
pubmed: 26883133
World J Oncol. 2019 Apr;10(2):90-100
pubmed: 31068989
Transl Lung Cancer Res. 2020 Aug;9(4):967-970
pubmed: 32953477
Strahlenther Onkol. 2014 Nov;190(12):1125-32
pubmed: 25098688
Anticancer Res. 2018 Sep;38(9):5261-5265
pubmed: 30194176
World J Oncol. 2020 Jun;11(3):98-105
pubmed: 32494316
Eur J Cancer. 2017 Oct;84:212-218
pubmed: 28826074
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Clin Lung Cancer. 2017 Jul;18(4):e243-e249
pubmed: 28065620
J Cancer. 2020 Jan 1;11(6):1334-1340
pubmed: 32047540
N Engl J Med. 1999 Jan 28;340(4):265-71
pubmed: 9920950
Adv Ther. 2020 Mar;37(3):1145-1155
pubmed: 32002809
Lung Cancer (Auckl). 2018 Aug 16;9:49-55
pubmed: 30323698
Int J Surg. 2020 Dec;84:25-40
pubmed: 33086147
Cancer Immunol Immunother. 2018 Mar;67(3):459-470
pubmed: 29204702
Strahlenther Onkol. 2018 Oct;194(10):876-885
pubmed: 29774395
Lung. 2016 Aug;194(4):625-9
pubmed: 27140191
J Thorac Oncol. 2020 Apr;15(4):618-627
pubmed: 31870883
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105
pubmed: 23813929
Clin Lung Cancer. 2020 Mar;21(2):e84-e88
pubmed: 31948903
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Ther Adv Med Oncol. 2020 Aug 11;12:1758835920942378
pubmed: 32849916
J Cancer. 2016 Oct 17;7(14):2012-2017
pubmed: 27877216
Radiat Oncol. 2020 Nov 2;15(1):252
pubmed: 33138845
Int J Clin Oncol. 2018 Aug;23(4):634-640
pubmed: 29442281
JAMA Oncol. 2019 Jan 1;5(1):11-12
pubmed: 30422210
J Thorac Oncol. 2019 Feb;14(2):237-244
pubmed: 30316010